Stonehaven Incubate appoints Charlie Dawson as Venture Partner

31st January, 2020

Charlie Dawson has been appointed as Venture Partner at Stonehaven Incubate, adding to the established team, to identify new opportunities for animal health spin-outs and support partners with opportunity evaluation and growth.

He has over 20 years of experience in strategy, marketing and leadership in the life sciences sector. Prior to joining Stonehaven Incubate, he led the transformational restructure of two major pharmaceutical companies and generated savings of up to US$50 million in capital.

Charlie Dawson says: “I’m delighted to have this opportunity to lead breakthrough growth for entrepreneurs and build strategies for new stand-alone animal health companies. In the next decade, we can expect to see many exciting developments in the animal health sector and Stonehaven Incubate will be here to support those prospects.”

Welcoming Charlie to the team, Mark Heffernan, CEO of Stonehaven Incubate, says: “We are particularly pleased to have an individual such as Charlie join our management team. He brings a wealth of industry experience which will help to identify disruptive opportunities in human health and apply these applications in animal health.

“With his leadership experience we are confident he will help transform the growing animal health industry through funding opportunities, business development and partnering.”

Between 2001 and 2017 Charlie held senior roles at Novartis Animal Health, Novartis Consumer Health and GSK Consumer Health. Later, he founded GRO Strategies and worked as a Senior Advisor at Stonehaven Consulting.

For further information, go to


Notes to editor:

Stonehaven Incubate

Swiss based Stonehaven Incubate was formed in February 2018 and is a dedicated, animal health group committed to creating new companies de novo from disruptive human technology. Stonehaven Incubate works with innovators and builds strategies for new, stand-alone animal

health companies. It finds experienced management teams and sources the required capital, leaving no stone unturned in its quest to bring human innovations to animal health.

Its major shareholder, Stonehaven Holding AG, was formed in 2017 by George Gunn and Matthias Hofer.

For more information contact Mike Keeler or Alistair Moses at Garnett Keeler PR on +44 (0)20 8647 4467 or /